Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Last trade$23.62
Day change-$1.20 (-4.83%)
Day range$23.43 – $25.12
Volume186,457
Market cap$1.47B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.47B
Price / earnings
—
Price / book
3.76×
Price / sales
73.57×
EV / sales
69.83×
EV / EBITDA
-8.38×
Profitability
Earnings per share
-$2.54
Return on assets
-35.95%
Return on equity
-38.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
20.07×
Quick ratio
20.07×
Cash ratio
3.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$121.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RAPP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$20M
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$20M
$0
$0
$0
$0
$0
Selling, general and administrative
$9.77M
$9.39M
$11.5M
$8.25M
$7.71M
$6.82M
$7.54M
$6.32M
Research and development
$34.32M
$51.41M
$32.72M
$30.26M
$22.28M
$22.68M
$19.57M
$17.2M
Total operating expenses
$44.09M
$60.81M
$44.22M
$38.51M
$29.99M
$29.5M
$27.11M
$23.52M
Operating income
-$44.09M
-$60.81M
-$24.22M
-$38.51M
-$29.99M
-$29.5M
-$27.11M
-$23.52M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$40.24M
-$56.62M
-$19.86M
-$33.76M
-$26.93M
-$26.73M
-$24.06M
-$19.98M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$40.24M
-$56.62M
-$19.86M
-$33.76M
-$26.93M
-$26.73M
-$24.06M
-$19.98M
Net income attributable to common shareholders
-$40.24M
-$56.62M
-$19.86M
-$33.76M
-$26.93M
-$26.73M
-$24.06M
-$19.98M
EBITDA
-$43.89M
-$60.59M
-$23.99M
-$38.24M
-$29.73M
-$29.24M
-$26.86M
-$23.26M
Basic earnings per share
-$0.84
-$1.19
-$0.42
-$0.72
-$0.71
-$0.75
-$0.68
-$0.56
Diluted earnings per share
-$0.84
-$1.19
-$0.42
-$0.72
-$0.71
-$0.75
-$0.68
-$0.56
Recent news
Company coverage with links to the original publishers.
Rapport Therapeutics announced positive Phase 2 trial results for RAP-219 in treating acute bipolar mania, meeting primary and secondary endpoints with statistically significant placebo-adjusted improvements in YMRS scores (3.1 points, p=0.045) and CGI-BP mania severity (0.4 points, p=0.024). The drug demonstrated favorable tolerability with no severe adverse events, establishing clinical proof-of-concept for its novel TARPγ8-selective mechanism. Phase 3 trials are expected to begin in the second half of 2027.
Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.
Rapport Therapeutics announced it will present Phase 2a trial results for RAP-219, a potential first-in-class AMPA receptor negative allosteric modulator, at the 2026 American Academy of Neurology Annual Meeting in Chicago on April 21. The presentation will include new 8-week follow-up data on efficacy and tolerability in focal onset seizure patients. RAP-219 is being evaluated for multiple neurological and psychiatric indications including seizures, bipolar disorder, and neuropathic pain.
Rapport Therapeutics announced a public offering of 9,615,385 shares of common stock at $26.00 per share, expecting to raise approximately $250 million. The offering is expected to close on September 11, 2025, with Goldman Sachs, Jefferies, TD Cowen, and Stifel acting as joint book-running managers.
Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.